Drug Innovation

Emory’s commitment to drug discovery stretches back three decades.

At that time, a new virus—eventually termed human immunodeficiency virus (HIV)—began claiming lives with sobering efficiency.

Among scientists the world over wanting to make a difference, three Emory researchers did.

The collaboration of Dennis Liotta, Raymond Schinazi, and Woo-Baeg Choi eventually yielded Emtriva and Epivir, which are components of a number of combination therapies used to treat HIV. More than 90 percent of US patients take drug combinations that include one or the other.

Other life-enhancing drugs—Baricitinib to battle COVID-19, Belatacept to aid successful kidney transplant, Obizur to treat bleeding episodes in adults with acquired hemophilia, ERDRP-0519 to target the measles morbillivirus, and Telbivudine to treat hepatitis B—were developed here at Emory.

Read about Emory drug hunters’ journey to discovery

Additional Information

Drug Discovery Resources

Emory's internal offices dedicated to drug discovery and research and our partnerships with others

Drug Discovery Fact Sheet

Easy-to-understand and use facts about the what, why, and how of Emory drug discovery

Videos

Hear from the inventors and scientists on the frontlines of drug discovery at Emory